A Phase 2 Randomized, Double-Blind, Placebo-Controlled, 2-Arm, Multi-Center Study Comparing Tivozanib Hydrochloride In Combination With Paclitaxel Versus Placebo In Combination With Paclitaxel in the Treatment of Subjects With Locally Recurrent and/or Metastatic Triple Negative Breast Cancer.
Phase of Trial: Phase II
Latest Information Update: 30 Jun 2015
At a glance
- Drugs Tivozanib (Primary) ; Paclitaxel
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms BATON-BC
- Sponsors AVEO Oncology
- 31 Aug 2018 Biomarkers information updated
- 30 Jan 2014 Status changed from recruiting to discontinued due to insufficient enrolment as reported in an AVEO Oncology media release.
- 21 Aug 2013 New source identified and integrated (Memorial Sloan-Kettering Cancer Center; 13-047).